A 16-week, Randomised, Double-blind, Placebo-controlled, Single-centre Study to Investigate Fluid Retention in Insulin-treated Subjects With Type 2 Diabetes Mellitus and Varying Degrees of Autonomic Neuropathy When Administered Rosiglitazone 4mg Twice Daily
Phase of Trial: Phase III
Latest Information Update: 26 Sep 2016
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 15 Oct 2008 Actual start date changed from Oct 2004 to Nov 2003 as reported by ClinicalTrials.gov.
- 09 Feb 2007 New trial record.